Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Polivy

Polivy 30 mg powder for concentrate for solution for infusion. Polivy 140 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 11

HOS-142653 · Präparat HOS-098846

In previously treated DLBCL patients treated with Polivy plus BR:  The most frequently reported (≥ 30%) ADRs (all grades) in patients treated with Polivy plus BR in previously treated DLBCL were neutropenia (45.7%), diarrhoea (35.8%), nausea (33.1%), thrombocytopenia (32.5%), anaemia (31.8%) and neuropathy peripheral (30.5%).  Serious adverse reactions were reported in 41.7% of Polivy plus BR treated patients.  The most common serious adverse reactions reported in ≥ 5% of patients were: febrile neutropenia (10.6%), sepsis (9.9%), pneumonia (8.6%) and pyrexia (7.9%).  The ADR leading to treatment regimen discontinuation in > 5% of patients treated with Polivy plus BR was thrombocytopenia (7.9%).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.